2021年11月23日

韓國健康AI公司忙著開發全球市場바로가기기자명金正日Chan-hyuk韓國健康人工智能解決方案提供商加速進入外國市場的努力。深生物周二表示,該公司與一家公司達成了戰略合作夥伴關係在歐洲,另一個在印度提高競爭力DeepDx前列腺癌、前列腺癌診斷輔助軟件,和在國際市場銷售產品。Lunit的乳腺癌檢測產品,Lunit洞察力CXR MMG,最近獲得了FDA的批準。更具體地說,深生物將與巴黎TRIBVN醫療和印度Morphle實驗室。根據深生物,TRIBVN醫療世界各地提供數字病理的解決方案。深生物預計DeepDx前列腺可以創建一個協同效應結合CaloPix時,TRIBVN醫療的主要解決方案,幫助各種癌症的診斷。Morphle實驗室是一個數字病理幻燈片掃描儀製造商。該公司正在成為未來公司從Y Combinator獲得投資後,美國啟動加速器。Morphle實驗室的掃描儀相比相對較小的通用數字病理笨重且昂貴的掃描儀。深生物也為海外市場研究與外國公司合作。 With HealthCare Konnect (HCK), a Swiss medical device distributor, Deep Bio analyzes medical AI markets in Europe and Africa to advance into those markets. Deep Bio aims to expand the geographic influence of DeepDx Prostate on pathology diagnosis institutions in Switzerland, Morocco, Algeria, Tunisia, and Egypt, the company said. “We are expanding our presence in the global market by introducing our innovative digital pathology software through close collaboration with companies in various countries,” said Kim Sun-woo, CEO of Deep Bio. Deep Bio will continue to seek active partnerships with foreign companies to expand the use of DeepDx Prostate, which provides faster and more consistent analysis results, and do its best to improve the global prostate cancer pathology diagnosis environment, Kim added. Lunit, another Korean health AI solution company, is also getting ready to expand the business into the global market. Earlier this month, Lunit scored the FDA approval for AI-backed imaging analysis solution Lunit Insight CXR Triage and a breast cancer detection product Lunit Insight CXR MMG. The company recently appointed Ken Nesmith as a chief business officer (CBO) of Lunit SCOPE, Marcus Skovhus as vice president of corporate development, and Park Su-bok as director of clinical strategy at Lunit INSIGHT. The new executives are expected to establish a long-term plan, regulation responses, and business strategies. “In the short term, we will work with overseas medical device companies to raise sales of diagnostic AI solutions. In the long term, we will discover and sell biomarkers in the treatment field,” a Lunit official said. “We will establish detailed strategies for entry into the global markets with foreign experts that we recently scouted.”